Abdi İbrahim will Continue its Investments in 2021
Abdi İbrahim CEO Süha Taşpolatoğlu said, "We will continue our domestic investments in 2021. Our new investments in our production facilities will also be on our agenda. We are working to implement our investment plan of approximately 150 million dollars."
Abdi İbrahim CEO Süha Taşpolatoğlu said, “We will continue our domestic investments in 2021, and new investments in our production facilities will be on our agenda. We are working to implement our investment plan of approximately 150 million dollars.' said.
Explaining that the pandemic caused by Kovid-19, which emerged in 2019 and started to spread rapidly in 2020, brought along a very unusual period for both Turkey and the world, Taşpolatoğlu said that the health, medicine and pharmaceutical sectors are at the center of this process.
He noted that Abdi İbrahim, as a well-established pharmaceutical company of 108 years and the industry leader for 18 years, is working to provide the highest level of contribution expected from it, taking into account the needs of the society in this difficult period.
On the other hand, Taşpolatoğlu explained that they are focused on making the best possible use of 2020 in terms of business goals, and gave the following information:
We started 2020 with the goals of strengthening our market share, strengthening our leadership that has been going on for 18 years, accelerating our R&D and innovation investments, and realizing our projects in the field of sustainability. With the pandemic that entered our agenda in March, we quickly reviewed our priorities, plans and strategies. We have determined our most important priority as ensuring the continuity of our people's access to medicines by taking all additional measures regarding the health of our employees. We continued our production activities in our facilities.
On the other hand, in order to be a part of the solution, we put our R&D and production power, medical competencies, and all our expertise and experience into the service of medicine. Right after the first cases were seen in our country, we obtained the raw material of the drug with chloroquine phosphate active ingredient, which is included as the primary treatment in the treatment protocol of our Ministry of Health for Kovid-19, from India and China under extraordinary conditions.
We donated 1.6 million tablets to the Ministry of Health, and 250 thousand tablets to Algeria and Kazakhstan, where our factories are located. We have committed to donate it to our ministry by producing it if there is an additional need until the end of the year. Subsequently, we completed the technology transfer of the drug with the active ingredient Favipiravir, which was developed by Novelfarma, one of the players of our industry, and entered the Kovid-19 treatment protocol, in a period of 1 week, and we produced the drug rapidly, and we still continue to produce it in line with the needs.'
- 'We continued our planned investments without interruption'
Taşpolatoğlu stated that as Abdi İbrahim, they follow their long-term strategy and goals, while the atmosphere of concern caused by the pandemic prevails all over the world and plans are postponed all over the world, and said:
'We bought OM Pharma, one of the leading biotechnological pharmaceutical companies in Switzerland, with a Swiss joint venture group. Thus, we achieved the title of the first Turkish pharmaceutical company to become a strategic partner to a western pharmaceutical company. By taking such an assertive step in difficult times, we were happy to represent our industry abroad and to demonstrate our strength with a move that made a sound globally. While making this purchase abroad, we did not delay our investments in our country. Despite the pandemic environment, we continued our planned investments in Esenyurt Production Facilities without interruption.'
- 'No matter what the conditions are, we maintain our investment excitement'
Taşpolatoğlu stated that the activities they will carry out with OM Pharma came to the fore in their 2021 agenda and said that they have the opportunity to produce some of the products in the chemical drug portfolio of OM Pharma at the facilities in Esenyurt for the whole world and to export them to world markets.
'Within the framework of the OM Pharma partnership, we aim to develop new biotechnological products thanks to the 250 million Swiss Francs we will allocate to biotechnology R&D in the next 5 years.' Taşpolatoğlu, on the other hand, said, "Thanks to this partnership, we will open up to new markets, especially the Latin America, China and USA pharmaceutical markets, where it is not currently active, and sell and sell OM Pharma's products in markets where Abdi İbrahim is currently active but OM Pharma is not present." He said that they aim to grow by marketing.
Explaining that Abdi İbrahim has grown with investments, Taşpolatoğlu used the following statements regarding the 2021 plans:
'We are a company that loves investment, we maintain our investment enthusiasm regardless of the circumstances. We will continue our domestic investments in 2021, and new investments in our production facilities will also be on our agenda. We are working to implement our investment plan of approximately 150 million dollars. Investment in our vocabulary; means production, employment and export... In 2020, we were aiming to increase our production capacity to 500 million boxes.
Today, we have reached approximately 420 million boxes with the improvement investments made. We have reached about 80% of our target. When the investments of our new production facility are completed, our actual production capacity will reach the level of 750 million boxes by 2022. Employment will also continue to be an extremely important priority for us. Currently, we are a large and strong family with a total of 4,600 employees in domestic and international production, field and headquarters. We want to move forward by walking together towards the goals we have set in 2021, and by filling our missing staff in line with the needs arising from our activities.'
- 'We will always work to raise the bar with our brave breakthroughs in 2021'
Abdi İbrahim CEO Süha Taşpolatoğlu stated that they will continue to provide production services to the most powerful pharmaceutical companies in the world in 2021 and that the field of production services will continue to maintain its priority and importance for them.
Explaining that developing innovative products in the field of consumer health, which has been on the rise during the Kovid-19 pandemic period, will be another priority area, Taşpolatoğlu noted that they will also focus on the 'Equivalent Drugs with Added Value' category.
Explaining that they will focus on the issue of sustainability in 2021 as well as commercial activities, Taşpolatoğlu said that they will accelerate their efforts in line with their goal of reducing their carbon footprint to zero in 2030.
Taşpolatoğlu concluded his statement as follows:
'In 2021, we will always work to raise the bar with our brave breakthroughs, our responsibility towards our country and our passion for our work. In addition to our successful economic performance, we aim to create value for all our stakeholders in the fields of environmental, social and governance, and to implement various projects, primarily 'social innovation in health', within the health ecosystem we are in.'